Impact of intravitreal ranibizumab, aflibercept and bevacizumab on retinal ganglion cell and nerve fibre layer thickness in Neovascular age-related macular degeneration

Abstract

Purpose: To compare the effects of monotherapy with intravitreal ranibizumab, aflibercept and bevacizumab on retinal ganglion cell layer (RGCL) and retinal nerve fibre layer (RNFL) in patients with naïve neovascular age-related macular degeneration (nAMD). Methods: This is a retrospective cohort study with three-groups comparison. 83 patients and 97 eyes on continuous monotherapy with an intravitreal anti-vascular endothelial growth factor (anti-VEGF) were followed for 24months and divided into three groups according to anti-VEGF (aflibercept: 25 eyes, ranibizumab: 34 eyes, bevacizumab: 38 eyes). Main outcome measures included: RGCL and RNFL thickness, best corrected visual acuity (BCVA), central macular thickness (CMT), macular volume (MV) and the presence of intraretinal fluids (IRF), subretinal fluids (SRF) and retinal pigment epithelial atrophy (RPE-atrophy). All outcome measures were recorded at the time of the first injection, 1 and 2years after treatment and compared longitudinally and between groups. Results: The mean age was 79±7years. The RGCL thickness, MV, CMT and the presence of IRF and SRF decreased significantly within all three medication groups (p<0.05 for all) with no significant difference between groups over the 2-year follow-up period (p>0.10 for all). The decrease in RNFL thickness was not significant within or between the groups after a 2-year follow-up (p>0.055 for all). RPE-atrophy increased significantly after 2 years in all three groups (p<0.028 for all) with no significant difference between groups at all three time points (p>0.307 for all). BCVA was comparable between the three groups over the 2-year follow-up period (p>0.22 for all). Conclusions: Monotherapy with intravitreal aflibercept, bevacizumab and ranibizumab was associated with comparable significant decreases in RGCL thickness, CMT, MV, IRF and SRF in naïve nAMD patients during the first 2 years of treatment. Furthermore, no significant differences either in BCVA or RNFL thickness were observed between the three intravitreal anti-VEFGs during the first 2 years of treatment.